Logo


Rewind 2018: Tough regulatory regime for pharmaceutical industry

The falling rupee, however, helped firms offset the impact of input cost hikes in the second quarter

The revenue from operations declined to ~69.7 bn for the fourth quarter against ~71.3 bn during the same period last year

It was a rough year for the pharmaceutical industry in more ways than one. Apart from the ban on over 300 fixed-dose combinations, and the rise in prices of bulk drugs because of manufacturing slowdown in China, there were signs of volatility in domestic sales because of the base effect of the goods and services tax (GST) implemented in 2017.  The falling rupee, however, helped firms offset the impact of input cost hikes in the second quarter. Exports were buoyant, hitting $11 billion in the April-October period.  It is expected to cross the ...